Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
about
PI3K/AKT/mTOR Pathway in AngiogenesisTranslatability scoring in drug development: eight case studiesEpidermal growth factor receptor blockers for the treatment of ovarian cancerInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsSilencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer.EGFR/HER-targeted therapeutics in ovarian cancerHelicobacter pylori and interleukin-8 in gastric cancerEpidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyThe tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent mannerUltrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.HER2 expression as a potential marker for response to therapy targeted to the EGFR.Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Cancer prevention by tea: animal studies, molecular mechanisms and human relevance.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerHigh level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesDecreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat padPresent and future evolution of advanced breast cancer therapy.Chemical proteomics: terra incognita for novel drug target profiling.New approaches in angiogenic targeting for colorectal cancer.A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformationsMolecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.Targeted inhibition of kinases in cancer therapyFoxM1 is a downstream target and marker of HER2 overexpression in breast cancerIdentification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.The role of alpha-blockers in the management of prostate cancerTargeting the epidermal growth factor receptorGefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalizationGefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.Cellular responses to EGFR inhibitors and their relevance to cancer therapy.Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.ZD6474--clinical experience to date.
P2860
Q21129332-4D09BD82-7F7A-4154-85BF-103DAC01E042Q22241760-0CA8F4C4-5516-4058-95D0-C694825695BFQ24240840-2A1763C0-D5F0-48BA-8EBD-ADB8148CD09BQ24810622-D196F352-1562-4BDC-BD9D-76E1B9A78595Q24814041-B8FAACD8-AC37-4752-BDCE-96E8FCA83A64Q26863231-C4C3B844-477C-4EA5-8076-8C2D2AB37551Q26999701-E204812C-C227-411A-AB44-51D014DFC4B1Q28475894-CE599837-AFDD-4C10-AD13-658845DCDD6EQ28534476-EBE24DD7-DDD7-4AE9-A398-D87756DEEF34Q30359568-25CD7F2F-D917-42A0-A238-B8D8B7B05350Q30538161-D7546582-D4ED-46CA-8F8B-FBA780B010DAQ33240248-367E4B0A-740D-4DEF-B4FC-C0A66B9BE45BQ33600807-4D2F1CFF-D99F-4224-AB9D-58F4061B822DQ33644407-9F017C94-89D1-4DE3-B155-51D117EE214BQ33693371-62BCBA48-9D98-4D6C-A9CE-8B6E9EAEE773Q33710152-EE04B5EE-6899-44D9-A229-4C475C3D16A2Q33717222-5A6949B1-70B8-4038-9B45-E5C026931246Q33892582-8D149321-9784-40B6-82C1-7E5EB205D4DCQ34036041-0D89F199-BBF9-444E-A9CF-68B47D36AF18Q34088424-C96EBF95-19CD-4379-A643-BA6217684331Q34140418-A23573D0-C9D9-48ED-834C-26397B0CDBFFQ34274925-B82938E7-E395-4B3A-97E0-3A32B9FBECE1Q34284580-755ED88F-9735-43EA-B170-3D7518538DACQ34382785-85B6F592-A403-4FE5-8BDC-8D9D8AD51932Q34492884-6A3082BE-8BDE-4DF9-84EE-22284E4CFB27Q34560236-1CD8ACB0-75B0-46FF-BD81-BA4AF81DA617Q34605162-EA1F73B1-6D9E-46AF-92C7-9137E62DBDF0Q34683348-756CEF59-119D-459C-90B2-0F9D4233BF12Q34725700-2F870B6A-C0EB-4935-8B64-A2391721DD26Q35030421-8A3A5642-ECDD-4095-954A-42A782D7C414Q35039999-5DEB3705-2FEB-45A7-BAD3-CA0FFFB76B42Q35784033-0A8ED356-CA89-4498-BEE3-52D313503D3BQ35828552-6D0809F2-31E4-4F15-A8F2-F25A06BB5604Q35890736-87D0C6CA-15D2-4DDA-BC74-B003DAA7225EQ35893456-32D68895-6ECB-48CE-9698-AA06F4E6AF21Q35990886-BD5C23EC-76BF-4D03-9555-59CA2C3BD2D5Q36003118-AB3EC29D-1A47-40DA-B1F8-D481D5B70617Q36032533-90E087BA-6283-4DAC-984F-5D1E3ED8408DQ36048159-6E2801E9-8970-495A-B0E2-329640438691Q36146882-097BBEE3-27BB-4067-9963-EA364C69A4DE
P2860
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@en
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@nl
type
label
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@en
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@nl
prefLabel
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@en
Inhibition of growth factor pr ...... tor tyrosine kinase inhibitor.
@nl
P2093
P1476
Inhibition of growth factor pr ...... ptor tyrosine kinase inhibitor
@en
P2093
A R Bianco
F Ciardiello
S De Placido
P304
P407
P577
2001-05-01T00:00:00Z